NCT06044077View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,920

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

March 8, 2024

Study Completion Date

July 31, 2029

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

BIOLOGICAL

control pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp

Trial Locations (1)

Unknown

RECRUITING

Sichuan Center For Disease Control and Prevention, Chengdu

All Listed Sponsors
lead

Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

INDUSTRY